Diabetes therapy : research, treatment and education of diabetes and related disorders
Diabetic Ketoacidosis and Severe Hypoglycemia Risks with Ipragliflozin/Insulin Versus Insulin in Type 1 Diabetes: A Japanese Real-World Database Study.
Tomoyuki Kawamura, Takumi Lee, Mami Shintani-Tachi, Izuru Terada, Naoko Wakasugi
Published: 202610.1007/s13300-025-01815-7
Abstract
INTRODUCTION: Ipragliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved in Japan as an adjunct to insulin therapy for the management of type 1 diabetes (T1D). Diabetic ketoacidosis (DKA) and severe hypoglycemia (SH) have been speci…
Preview only. Read the full abstract at the source